ArticleFrontiers in digital health2026
Quality assessment of large language model-generated prior authorization letters in nephrology.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond social media: the era of generative AI and intelligent digital platforms in nephrology education.Renal failure · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prior authorization (PA) is a major source of administrative burden, treatment delay, and clinician burnout. Artificial intelligence (AI), particularly large language models (LLMs), is increasingly used to assist with clinical documentation, yet its reliability for payer-facing administrative tasks remains uncertain. Objective: To evaluate the quality of PA letters drafted by ChatGPT-5 for commonly used medications requiring PA in nephrology. Quality was evaluated based on correctness and strength of clinical reasoning. Methods: We created a single standardized prompt and applied it across 29 nephrology scenarios to generate PA letters. Each PA letter was reviewed against four criteria: 1) absence of false statements or hallucinations, 2) correctness of ICD-10 coding, 3) presence and validity of citations, and 4) clinical reasoning, rated on a 4-point Likert scale (illogical, weak, adequate and strong). FDA drug labels, KDIGO guidelines and related randomized controlled trials were used as reference standards. Results: Out of 29 letters, one letter (3.5%) contained false statements mentioning an irrelevant clinical trial. The ICD-10 diagnosis code was correct in 23 letters (79.3%), most errors were related to chronic kidney disease (CKD) staging or internal diagnostic inconsistencies. 27 letters (93.1%) cited valid references, with one letter citing an incorrect trial and another one citing a correct KDIGO guideline with inaccessible link. Twenty-six letters (89.7%) demonstrated strong clinical reasoning, supported by guideline-oriented or FDA label-aligned justification. The remaining 3 letters were rated as adequate reasoning. The main areas for improvement involved citing relevant references and emphasizing special considerations, for example Risk Evaluation and Mitigation Strategy (REMS) compliance for eculizumab. Conclusions: ChatGPT-5 can generate clinically coherent PA drafts for nephrology medications, but limitations in coding precision and citation reliability persist. With appropriate oversight, AI-assisted documentation may reduce administrative burden while maintaining safety and accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.